Pulmonary vascular disease & thromboembolism
SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension
Main finding · Change in peak oxygen uptake from baselineResult — go to the resultMean change 102.74 mL/min 95% CI 27.72–177.76Authors' conclusion
Improvements in right ventricular structure and function underscore the potential for sotatercept as a disease-modifying agent with reverse-remodeling capabilities.
Study context
- Population
- Pulmonary arterial hypertension, WHO functional class III, on combination background therapy21 completed 24 weeks
- Comparison
- Sotatercept, change from baseline
- Outcome
- Change in peak oxygen uptake from baseline
- Follow-up
- Week 24
Main finding
As reported in the abstract
Mean change
102.74 mL/min
95% CI 27.72–177.76
P = 0.0097
Week 24vs Baseline
mean change 102.74 mL/min (95% CI 27.72–177.76); P = 0.0097
Secondary outcomes
Resting and peak exercise hemodynamics, 6-minute walk distance
- Improvements vs baseline
RV function (CMR) · week 24
- Improvements from baseline in RV function
Original publication
SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension. Circ Heart Fail. Published 4 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →